Actos Sales Data

Last updated: February 2014 (updated quarterly).
The following data shows Actos U.S. retail sales in Q4 2013 compared to previous quarters.

Date Range Sales Rank Sales ($000) Units (000)
Q3 2012 39 (18) -41.96% -46.64%
Q2 2012 21 -8.94% -8.94%
Q1 2012 21 (3) -4.52% -12.97%
Q4 2011 18 (3) -15.22% -19.67%
Q3 2011 15 (6) -11.05% -12.03%
Q2 2011 9 -13.56% -4.89%
Q1 2011 9

* Units refer to the number of packages sold.

Source: IMS Health (Midas). Please review our terms of use and attribution guidelines. Copyright - All rights reserved. Unauthorized use and/or duplication of this material without express written permission is strictly prohibited.

Related News

DateArticle
September 27, 2013Takeda Responds to Verdict in Diabetes Drug Case
June 16, 2011Diabetes Drug Actos May Raise Risk for Bladder Cancer: FDA
June 16, 2011Actos (pioglitazone): Ongoing Safety Review - Potential Increased Risk of Bladder Cancer
June 16, 2011Takeda Responds to U.S. Food and Drug Administration Update to Safety Review of Actos (pioglitazone HCl)
September 20, 2010US Agency Probes Risks Of Bladder Cancer With Diabetes Pill Actos, Rival To Glaxo's Avandia
February 15, 2010Diabetes Drugs Avandia, Actos Tied to Fractures in Women
August 18, 2009Avandia Raises Heart Failure Risk More Than Actos
December 10, 20082 Diabetes Drugs Double Fracture Risk in Women
December 10, 2008Popular Class of Diabetes Drugs Doubles Risk of Fractures in Women
November 24, 2008Avandia's Heart Risk Higher Than Others in Its Class
Hide
(web2)